Alpha Teknova reported record quarterly revenue for the third quarter of 2026, marking a 22% year-over-year increase. The performance was characterized by substantial growth in the Clinical Solutions segment and significant gross margin expansion, prompting management to raise its full-year revenue outlook.
Key Highlights
- Total revenue reached $12.7 million, exceeding the $11.77 million analyst estimate and reflecting record sales for the second consecutive quarter.
- Clinical Solutions revenue surged 86% to $3.2 million, while the core Lab Essentials segment grew 9% to $9.0 million.
- Gross margin expanded to 38.0% from 30.7% in the prior-year period, driven by higher volume and improved fixed cost absorption.
- The company raised its full-year 2026 revenue guidance to a range of $46 million to $48 million.
- Net loss narrowed to $0.06 per share, outperforming the anticipated $0.07 loss, while the balance sheet was strengthened by a $42.9 million net equity raise in October.